Novel and highly recurrent chromosomal alterations in Sézary syndrome.
暂无分享,去创建一个
Remco Dijkman | Karl-Johan Leuchowius | Ulf Landegren | Ola Söderberg | Karoly Szuhai | Maarten H Vermeer | U. Landegren | S. Whittaker | O. Söderberg | R. Willemze | R. van Doorn | J. Knijnenburg | K. Szuhai | M. Ijszenga | P. C. van Voorst Vader | Sylke Gellrich | X. Mao | M. Vermeer | S. Gellrich | J. J. Out-Luiting | R. Dijkman | C. Tensen | Jeroen Knijnenburg | Marije Ijszenga | Cornelis P Tensen | Xin Mao | Rein Willemze | Remco van Doorn | Sean Whittaker | Pieter C van Voorst Vader | Marie-Jeanne P Gerritsen | Marie-Louise Geerts | Jacoba J Out-Luiting | M. Geerts | M. Gerritsen | Karl‐Johan Leuchowius
[1] E. Jordanova,et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Willemze,et al. Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis , 2004, Cancer Research.
[3] H. Tanke,et al. Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. , 2007, Cancer genetics and cytogenetics.
[4] R. Clark,et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. , 2006, Blood.
[5] Eric B Haura,et al. Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.
[6] H. Tanke,et al. Insights from genomic microarrays into structural chromosome rearrangements , 2005, American journal of medical genetics. Part A.
[7] L. Morsberger,et al. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: Search for recurrent chromosome abnormalities , 2006, Genes, chromosomes & cancer.
[8] S. Whittaker,et al. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. , 2003, Blood.
[9] G. Evan,et al. Myc-Is this the oncogene from Hell? , 2002, Cancer cell.
[10] C. Geisler,et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells , 2001, Leukemia.
[11] J. Aster,et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.
[12] P. Bouillet,et al. Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Baylin,et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3 , 1995, Nature Genetics.
[14] I. D'Agnano,et al. Oligopeptides impairing the Myc‐Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity , 2007, Journal of cellular physiology.
[15] P. Nowell,et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[16] Carolina Wählby,et al. In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor β Using a Generalized Proximity Ligation Method* , 2007, Molecular & Cellular Proteomics.
[17] E. Sausville,et al. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Whittaker,et al. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. , 2003, Cancer research.
[19] P. Krammer,et al. CD95's deadly mission in the immune system , 2000, Nature.
[20] J. Cleveland,et al. Mnt Loss Triggers Myc Transcription Targets, Proliferation, Apoptosis, and Transformation , 2004, Molecular and Cellular Biology.
[21] S. Whittaker,et al. Molecular cytogenetic characterization of Sézary syndrome , 2003, Genes, chromosomes & cancer.
[22] Rob Leurs,et al. CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. , 2003, Blood.
[23] A. Puisieux,et al. A twist for survival and cancer progression , 2005, British Journal of Cancer.
[24] R. Dummer,et al. Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. , 2001, The Journal of investigative dermatology.
[25] C. Zahnow,et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. , 2004, Cancer cell.
[26] N. Neamati,et al. Small molecule inhibitors of Stat3 signaling pathway. , 2007, Current cancer drug targets.
[27] A. Ranki,et al. Notable losses at specific regions of chromosomes 10q and 13q in the Sézary syndrome detected by comparative genomic hybridization. , 1999, The Journal of investigative dermatology.
[28] Nicola Pimpinelli,et al. WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.
[29] Benjamin J. Raphael,et al. Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability, and cancer in mice , 2004 .
[30] R. Eddy,et al. The TCF8 gene encoding a zinc finger protein (Nil-2-a) resides on human chromosome 10p11.2. , 1992, Genomics.
[31] A. Wynshaw-Boris,et al. Inflammatory Disease and Lymphomagenesis Caused by Deletion of the Myc Antagonist Mnt in T Cells , 2006, Molecular and Cellular Biology.
[32] Céline Rouveirol,et al. Bioinformatics Original Paper Computation of Recurrent Minimal Genomic Alterations from Array-cgh Data , 2022 .
[33] Céline Rouveirol,et al. VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles , 2006, Bioinform..
[34] S. Baylin,et al. HIC1 hypermethylation is a late event in hematopoietic neoplasms. , 1997, Cancer research.
[35] P. Nowell,et al. Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. , 2006, The Journal of investigative dermatology.
[36] S. Whittaker,et al. Fine mapping of chromosome 10q deletions in mycosis fungoides and sezary syndrome: Identification of two discrete regions of deletion at 10q23.33–24.1 and 10q24.33–25.1 , 2005, Genes, chromosomes & cancer.
[37] L. Penn,et al. The myc oncogene: MarvelouslY Complex. , 2002, Advances in cancer research.
[38] A. Wynshaw-Boris,et al. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis , 2003, The EMBO journal.
[39] M. Henriksson,et al. Proteins of the Myc network: essential regulators of cell growth and differentiation. , 1996, Advances in cancer research.
[40] U. Landegren,et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.
[41] L. Staudt,et al. Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. , 2003, The Journal of biological chemistry.
[42] Remco Dijkman,et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. , 2005, Blood.
[43] B. Czepulkowski,et al. Molecular cytogenetic analysis of cutaneous T‐cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides , 2002, The British journal of dermatology.
[44] J. Scarisbrick,et al. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. , 2001, The Journal of investigative dermatology.
[45] H. Tanke,et al. COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping , 2006, Nature Protocols.
[46] A. Puisieux,et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. , 2004, Cancer cell.
[47] L. Penn,et al. Cancer therapeutics: targeting the dark side of Myc. , 2005, European journal of cancer.
[48] Louise C. Showe,et al. Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma , 2003, The Journal of experimental medicine.
[49] S. Lowe,et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.
[50] C. Croce,et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[51] A. Poustka,et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. , 2005, Cancer research.